ATE277637T1 - Verwendung von thexapyrin zur herstellung eines arzneimittels zur verwendung mit einem chemotherapeutikum in der krebs- chemosensibilisierung - Google Patents

Verwendung von thexapyrin zur herstellung eines arzneimittels zur verwendung mit einem chemotherapeutikum in der krebs- chemosensibilisierung

Info

Publication number
ATE277637T1
ATE277637T1 AT97903873T AT97903873T ATE277637T1 AT E277637 T1 ATE277637 T1 AT E277637T1 AT 97903873 T AT97903873 T AT 97903873T AT 97903873 T AT97903873 T AT 97903873T AT E277637 T1 ATE277637 T1 AT E277637T1
Authority
AT
Austria
Prior art keywords
thexapyrine
production
medicinal product
chemotherapeutic drug
glycoprotein
Prior art date
Application number
AT97903873T
Other languages
English (en)
Inventor
Richard A Miller
Stuart W Young
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Application granted granted Critical
Publication of ATE277637T1 publication Critical patent/ATE277637T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT97903873T 1996-01-25 1997-01-23 Verwendung von thexapyrin zur herstellung eines arzneimittels zur verwendung mit einem chemotherapeutikum in der krebs- chemosensibilisierung ATE277637T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/591,318 US5776925A (en) 1996-01-25 1996-01-25 Methods for cancer chemosensitization
PCT/US1997/000907 WO1997026915A1 (en) 1996-01-25 1997-01-23 Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization

Publications (1)

Publication Number Publication Date
ATE277637T1 true ATE277637T1 (de) 2004-10-15

Family

ID=24366012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97903873T ATE277637T1 (de) 1996-01-25 1997-01-23 Verwendung von thexapyrin zur herstellung eines arzneimittels zur verwendung mit einem chemotherapeutikum in der krebs- chemosensibilisierung

Country Status (14)

Country Link
US (1) US5776925A (de)
EP (1) EP0912196B9 (de)
JP (1) JP2000503989A (de)
KR (1) KR19990082024A (de)
CN (1) CN1093766C (de)
AT (1) ATE277637T1 (de)
AU (1) AU715025B2 (de)
DE (1) DE69730961T2 (de)
ES (1) ES2227671T3 (de)
HK (1) HK1018588A1 (de)
IL (1) IL125459A0 (de)
NO (1) NO983429L (de)
NZ (1) NZ331513A (de)
WO (1) WO1997026915A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US6200547B1 (en) * 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US6482436B1 (en) 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH10279502A (ja) * 1997-03-31 1998-10-20 Katsuro Tachibana 光感受性物質の励起方法
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
KR20010113642A (ko) 1999-01-13 2001-12-28 추후기재 약물의 효능을 증대시키기 위한 조성물 및 증대 방법
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US20030031676A1 (en) * 1999-10-29 2003-02-13 Pharmacyclics, Inc. Conjugate compounds for treating atheroma and other diseases
US7579338B2 (en) * 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
WO2001032210A2 (en) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7112671B2 (en) * 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
US6919327B2 (en) 2000-11-17 2005-07-19 Pharmacyclics, Inc. Texaphyrin coordination compounds and uses thereof
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
WO2003039327A2 (en) 2001-11-02 2003-05-15 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
WO2003049743A1 (en) * 2001-12-13 2003-06-19 Pharmacyclics, Inc. Combination cancer therapy
KR20040075001A (ko) * 2001-12-13 2004-08-26 파마사이클릭스, 인코포레이티드 신경계 진행에 영향을 주는 방법
US6984734B2 (en) 2002-02-26 2006-01-10 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040010218A1 (en) * 2002-07-11 2004-01-15 Henderson Barbara W. Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
US7981928B2 (en) 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
WO2005112759A1 (en) * 2004-05-20 2005-12-01 Pharmacyclics, Inc. A method of enhancing visualization of atherosclerotic plaque
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
US20060217291A1 (en) * 2005-03-25 2006-09-28 Ichiro Hirotsu Radiosensitizer
JP4972929B2 (ja) * 2005-03-25 2012-07-11 ニプロ株式会社 放射線増感剤
CN103784960A (zh) * 2005-07-27 2014-05-14 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
CN101287475B (zh) * 2005-09-07 2012-11-14 阿尔卡米亚肿瘤学股份有限公司 包含透明质酸和治疗抗体的治疗组合物以及制药用途
US20070072838A1 (en) * 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
US8440625B2 (en) * 2006-06-26 2013-05-14 University Of British Columbia Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
TWI445696B (zh) 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
CN106572991A (zh) 2014-06-11 2017-04-19 德克萨斯州大学系统董事会 用于克服铂耐受性的德克萨卟啉‑pt(iv)缀合物及组合物
EP3554475A4 (de) * 2016-12-13 2020-08-19 Health Research, Inc. Fotodynamische therapie (pdt) im nahinfrarotbereich (nir) in kombination mit chemotherapie
CA3189244A1 (en) 2020-08-14 2022-02-17 Jonathan L. Sessler Texaphyrin derivatives for manganese chemotherapy, photoacoustic imaging, and photothermal therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins

Also Published As

Publication number Publication date
NO983429D0 (no) 1998-07-24
NO983429L (no) 1998-09-24
ES2227671T3 (es) 2005-04-01
EP0912196B1 (de) 2004-09-29
WO1997026915A1 (en) 1997-07-31
HK1018588A1 (en) 1999-12-30
DE69730961D1 (de) 2004-11-04
NZ331513A (en) 2001-10-26
EP0912196B9 (de) 2005-01-05
CN1093766C (zh) 2002-11-06
AU1833397A (en) 1997-08-20
JP2000503989A (ja) 2000-04-04
AU715025B2 (en) 2000-01-13
KR19990082024A (ko) 1999-11-15
CN1213313A (zh) 1999-04-07
IL125459A0 (en) 1999-03-12
DE69730961T2 (de) 2005-11-24
EP0912196A1 (de) 1999-05-06
US5776925A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
ATE277637T1 (de) Verwendung von thexapyrin zur herstellung eines arzneimittels zur verwendung mit einem chemotherapeutikum in der krebs- chemosensibilisierung
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
BR9107070A (pt) Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral.
ES2174895T3 (es) Combinaciones metalicas complejas con contenido en carbenos heterociclicos.
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
BR9205645A (pt) Derivados de 2,4-diaminoquinazolinas para aumentar a atividade antitumoral
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
ATE272404T1 (de) Verwendung von taurolidine zur herstellung eines arzneimittels zur behandlung von leukämien
PL341151A1 (en) Substituted products of condensation of n-benzyl-3-indenylacetamides with heterocyclic aldehydes for use in treating neoplastic diseases
EP1359909A4 (de) Krebstherapie unter verwendung von triptolid-prodrugs
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
ES2151508T3 (es) Empleo de inhibidores de reductasa 3-hidroxi-3-metilglutaril coenzima a como una modalidad en la terapia del cancer.
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
IL114382A0 (en) Cancer therapy using lymphotoxin
ES8403884A1 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
WO1998003518A3 (en) New bis-platinum complexes with polymethylene derivatives as ligands having antitumor activity
CA2243392A1 (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
Ding Investigation of the additive potential of teniposide and vincristine in non-Hodgkin's lymphoma.
EP0428107A3 (en) Treatment of multi-drug resistant tumors with quinolyl- and isoquinolyloxazole-2-ones
MY105075A (en) Cancer treatment
AU1502388A (en) Use of odc inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma
JPS6413027A (en) Antitumor agent
AU648046B2 (en) Treatment of breast cancer with antigestagens
DE59000311D1 (de) Verwendung von suramin und physiologisch vertraeglichen derivaten davon, gegebenenfalls in kombination mit anti-androgenen mitteln zur herstellung von arzneimitteln zur behandlung des humanen prostatakarzinoms.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties